Neurotoxicity of MAO Metabolites of Catecholamine Neurotransmitters: Role in Neurodegenerative Diseases

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 101-115

  Burke, William J ^a,f   Li, Shu Wen ^a   Chung, Hyung D ^a   Ruggiero, David A ^b   Kristal, Bruce S ^c,d   Johnson, Eugene M ^e   Lampe, Patricia ^e   Kumar, Vijaya B ^a   Franko, Mark ^a   Williams, Evelyn A ^f   Zahm, Daniel S ^f  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b Columbia Univ Coll of Phys/Surg ^*  (United States)

^c BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3,4 Dihydroxyphenylacetaldehyde; 3,4 Dihydroxyphenylglycolaldehyde; Alzheimer's disease; Catecholamine metabolites; MAO; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; 3,4 DIHYDROXYPHENYLGLYCOLALDEHYDE; ADRENALIN; ALDEHYDE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOLAMINE; CHOLINESTERASE INHIBITOR; DOPAMINE; FREE RADICAL; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; NORADRENALIN; PACLITAXEL; PESTICIDE; ROTENONE; SELEGILINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; DEGENERATIVE DISEASE; ELECTRON SPIN RESONANCE; HUMAN; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TISSUE NECROSIS;

GYMNOMYZA SAMOENSIS;

EID: 9144224220     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00090-1     Document Type: Article

References (91)

1. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001;57:1515-7.
2. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osona M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1302-6.
3. Bondareff W, Mountjoy CD, Roth M. Loss of neurons of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982;32:164-8.
4. Blashko H. Amine oxidase and amine metabolism. Pharmacol Rev 1952;4:415-53.
5. Blashko H, Burn JH. Oxidation of adrenaline and noradrenaline by amine oxidase. J Phyisol 1951;112:37P.
6. Burke WJ, Chung HD, Marshall GL, Gillespie KN, Joh TH. Evidence for decreased transport of PNMT protein in advanced Alzheimer's disease. J Am Geriatr Soc 1990a;38:1275-82.
7. Burke WJ, Park DH, Chung HD, Marshall JH, Joh TH. Evidence for decreased transport of tyrptophan hydroxylase in Alzheimer's disease. Brain Res 1990;537:83-7.
8. Burke WJ, Chung HD, Marshall GL, Park DH, Joh TH, Commins DL, et al. Defective axonal transport: a mechanism in the degeneration of neurons in Alzheimer's disease. In: Morley JE, Coe RM, Strong R, Grossberg GT, editors. Memory function and aging-related disorders. New York (NY): Springer; 1992. p. 113-30.
9. Burke WJ, Galvin NJ, Chung HD, Stoff AD, Gillespie KN, Cataldo AM et al. Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease. Brain Res 1994a; 661:35-42.
10. Burke WJ, Coronado PG, Schmitt CA, Gillespie KN, Chung HD. Blood pressure regulation in Alzheimer's disease. J Autonom Nerv Syst 1994;38:65-71.
11. Burke WJ, Raghu G, Strong R. Taxol protects against calcium-mediated death of differentiated rat pheochromocytoma cells. Life Sci 1994;55:313-9.
12. Burke WJ, Schmitt CA, Li SW, Gillespie KN, Park DH, Joh TH. Simultaneous measurement of enzyme activity, protein, mRNA and metabolites in small samples. Anal Biochem 1995;230:345-8.
13. Burke WJ, Schmitt CA, Gillespie KN, Li SW. Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells. Brain Res 1996;722:232-5.
14. Burke WJ, Schmitt CA, Miller C, Li SW. Norepinephrine transmitter metabolite induces apoptosis in differentiated rat pheochromocytoma cells. Brain Res 1997;760:290-3.
15. Burke WJ, Kristal BS, Yu BP, Li SW, Lin TS. Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Res 1998;787:328-32.
16. Burke WJ, Chung HD, Li SW. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline in human tissues by microcolumn high-performance liquid chromatography. Anal Biochem 1999a;273:111-6.
17. Burke WJ, Li SW, Schmitt CA, Xia P, Chung HD, Gillespie KN. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death. Brain Res 1999;816:633-7.
18. Burke WJ, Li SW, Schmitt CA, Zahm DS, Chung HD, Conway AD, et al. Catecholamine-derived aldehyde neurotoxins. In: Storch A, Collins MA, editors. Neurotoxic factors in Parkinson's disease and related disorders. New York (NY): Kluwer Academic Publishers; 2000a. p. 167-80.
19. Burke WJ, Li SW, Conway A, Lin T-S, Chung HD. The mechanism of DOPEGAL neurotoxicity: implications for loss of adrenergic neurons in Alzheimer's disease. Neurology 2000;54:A315.
20. Burke WJ, Li SW, Zahm DS, MacArthur H, Kolo LL, Westfall TC et al. Catecholamine monoamine oxidase A metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res 2001;891:218-27.
21. Burke WJ, Li SW, Williams EA, Zahm DS. 3,4-Dihydroxyphenylacetaldehyde is toxic to dopamine neurons in vivo: implications for Parkinson's disease pathogenesis. Exp Neurol 2002 [submitted for publication].
22. Busciglio J, Lorenzo A, Yeh J, Yankner BA. B-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995;14:879-88.
23. Colzi A, Musolino A, Juliano A, Fomai F, Bonucceli U, Corsini GU, Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite, in in vivo dialysate from rat striatum. J Neurochem 1996;66:1510-6.
24. Conway KA, Rochet J-C, Bieganski RM, Lansbury PT. Kinetic stabilization of the α-synuclein adduct. Science 2001;294:1346-9.
25. Davis VE, Walsh MJ, Yamanaka Y. Augmentation of alkaloid formation from dopamine by alcohol and acetaldehyde in vitro. J Pharmacol Exp Therap 1970;174:401-12.
26. Davis VE, Cashaw JL, McLaughlin BR, Hamlin TA. Alteration of norepinephrine metabolism by barbiturates. Biochem Pharmacol 1974;23:1877-89.
27. Deckworth T, Johnson EM. Temporal analysis of apoptosis of sympathetic neurons deprived of nerve growth factor. J Cell Biol 1993;123:1207-22.
28. Duncan RJS. The preparation of some biochemically important aldehydes. Can J Biochem 1975;53:920-2,
29. Duncan RJS, Sourkes TL. Some enzymic aspects of the production of oxidized or reduced metabolites of catecholamines and 5-hydroxytryptamine by brain tissue. J Neurochem 1974;22:663-8.
30. Fahn S. Levodopa-induced neurotoxicity. CNS Drugs 1997;8:376-93.
31. Falkenburger BH, Barstow KL, Mintz IM. Dendrodendritic inhibition through reversal of dopamine transport. Science 2001;293:2465-70.
32. Fellman JH. The rearrangement of epinephrine. Nature 1958;182:311-2.
33. Filloux F, Townsend JJ. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 1993;119:79-88.
34. Fornai F, Giorgi FS, Bassi L, Ferrucci M, Alessandri MG, Corsini GU. Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment. Brain Res 2000;861:126-34.
35. Gai WP, Geffen LB, Denoroy L, Blessing WW. Loss of C-1 and C-3 epinephrine-synthesizing neurons in medulla oblongata in Parkinson's disease. Ann Neurol 1993;33:357-67.
36. Giasson BI, Lee VM-Y. A new link between pesticides and Parkinson's disease. Nat Neurosci 2000;3:1227-8.
37. Glover V, Sandler M. Dopamine is a monoamine oxidase B substrate in man. Nature 1977;265:80-1.
38. Goate A, Chartier-Harlin MC, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
39. Hagen TM. (R)-α-Lipoicacid supplemented old rats have improved mitochondrial function, decreased oxidative damage and increased metabolic rate. FASEB J 1998;13:411-8.
40. Halliwell B, Kaur H, Ingleman-Sundberg M. Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Radic Biol Med 1991;10:439-41.
41. Hashimoto M, Takeda A, Hsu LJ, Taknouchi T, Masliah E. Role of cytochrome C as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem 1999a;274:28849-52.
42. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuro Rep 1999b;10:717-21.
43. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
44. Hirsch EC, Facheux B, Damier P, Mouatt-Prigent A, Agid Y. Neuronal vulnerability in Parkinson's disease. J Neural Transm 1997;50:79-88.
45. Iqbal K, Zaidi T, Wen GY, Grundke-Iqbal I, Wisniewski HM. Defective microtubule assembly in Alzheimer's disease. Lancet 1986;i:421-6.
46. Kathakota S, Azuma T, Reinhard C, Klippel A, Tang J, Keting C et al. Caspase-3-generated fragment of gelsolin: effector of morphological changes in apoptosis. Science 1997;278:294-8.
47. 2 regulation of apoptosis. Science 1997;275:1132-6.
48. Kristal BS, Park BK, Yu BP. 4-Hydroxyenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem 1996;271:6033-8.
49. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW et al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 2001;30:924-31.
50. Lamensdorf I, Eisenhofer G, Harvey-White J, Neckustan A, Kirk K, Kopin IJ. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC 12 cells. Brain Res 2000a;868:191-201.
51. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ. Metabolic stress in PC 12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 2000;60:552-8.
52. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med 1998;339:1044-53.
53. Lassman H, Bancher C, Breitschopf H, Weigel J, Bobinski M, Jellinger K et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 1995;89:35-41.
54. Lataste H, Senilh V, Wright M, Guenard D, Potier P. Relationships between the structures of taxol and baccatine III derivatives and their in vitro action on the disassembly of mammalian brain and physarom ameobal microtubules. Proc Natl Acad Sci 1984;81:4090-4.
55. Lee VM, Bahn BJ, Otur SL, Trojanowski JD. A68: a major subunit of paired helical filaments and derivative of forms of normal tau. Science 1991;251:675-8.
56. Lee FJS, Liu ZB, Pristupa JB, Niznik HB. Direct binding and functional coupling of α-synuclein to dopamine transporters accelerates dopamine-induced apoptosis. FASEB J 2001;15:916-26.
57. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2002;277:5411-7.
58. Leeper L, Weissbach H, Udenfriend S. Studies on the metabolism of norepinephrine, epi nephrine and their O-methyl analogs by partially purified enzyme preparations. Arch Biochem Biophys 1958;77:417-27.
59. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten year follow-up of three different initial treatments in de-novo PD: a randomized trial. 2001;57:1687-94.
60. Li SW, Elliott WH, Burke WJ. Synthesis of a biochemically important aldehyde, 3,4-dihydroxyphenylglycolaldehyde. Bioorg Chem 1994;22:337-42.
61. Li SW, Spaziano VT, Burke WJ. Synthesis of a biochemically important aldehyde, 3,4-dihydroxyphenylacetaldehyde. Bioorg Chem 1998;26:45-50.
62. Li SW, Lin T-S, Minteer, Burke WJ. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Mol Brain Res 2001;93:1-7.
63. Liu J, Mori A. Monoamine metabolism provides an antioxidant defense in brain against oxidant-and free radical-induced damage. Arch Biochem Biophys 1993;302:118-27.
64. Liu J, Killilea D, Ames BN. Age-associated mitochondrial oxidative decay: improvement carnitine acetyltransferase substrate binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-α-lipoic acid. Proc Natl Acad Sci 2002 [in press].
65. Mattammal MB, Chung HD, Strong R. Confirmation of a dopamine metabolite in Parkinsonian brain tissue by gas chromatographymass spectrometry. J Chromatogr 1993;205:205-12.
66. Orrenius S, Nicotera P. The calcium ion and cell death. J Neural Transm 1994;43(suppl):1-11.
67. Piao YS, Wakabayashi K, Hayashi S, Yoshimoto M, Takahashi H. Aggregation of alpha-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Clin Neuropathol 2000;19:163-9.
68. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Deheja A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
69. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to B-amyloid-induced neurotoxicity. PNAS 2002;99:6364-9.
70. Renson J, Weissbach H, Udenfriend S. Studies on the biological activities of the aldehydes derived from norepinephinr, serotonin, tryptamine and histamine. J Pharmacol Exp Therap 1964;143:326-31.
71. Rivett AJ, Eddy BJ, Roth JA. Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain. J Neurochem 1982;39:1009-16.
72. Robbins JH. Preparation and properties of p-hydroxyphenylacetaldehyde and 3-methoxy-4-hydroxyphenylacetaldehyde. Arch Biochem Biophys 1966;114:576-84.
73. Sandler M, Carter SB, Hunter KR, Stern GM. Tetrahydroisoquinoline alkaloids in vivo metabolites of L-dopa in man. Nature 1973;241:439-43.
74. Scarlett SL, Murphy MP. Release of apoptogenic proteins from mitochondrial intermembrane space during mitochondrial permeability transition. FEBS Lett 1997;418:282-6.
75. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-7.
76. 10 in the etiology and treatment of Parkinson's disease. Biol Factors 1999;9:267-72.
77. Stadlan N, Schmitt CA, Chung HD, Burke WJ. Taxol reduces stroke size in rat stroke model. Soc Neurosci 1994;20:A188.
78. Storch A, Schwarz J. The dopamine transporter: involvement in selective dopaminergic neurodegeneration. In: Storch A, Collins MA, editors. Neurotoxic factors in Parkinson's disease and related disorders. New York (NY): Kluwer Academic Publishers; 2000. p. 17-40.
79. Stoyanovsky DA, Cederbaum AI. ESR and HPLC-EC of ethanol oxidation to 1-hydroxyethylradical: rapid reduction and quantification of PDBN and PBN nitroxides. Free Radic Biol Med 1998;25:536-45.
80. Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH et al. Hypothesis: microtubule instability and paired helical filament formation in Alzheimer disease brain are related to apoliporotein E genotype. Exp Neurol 1994;125:163-71.
81. Tabakoff B, Anderson R, Alinsatos SGA. Enzymatic reaction of biogenic aldehydes in brain. Mol Pharmacol 1973;9:428-36.
82. Tank WA, Weiner H. Ethanol-induced alteration of dopamine metabolism in rat liver. Biochem Pharmacol 1979;28:3139-47.
83. Taylor PJ, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002;296:1991-5.
84. Tottmar O. Assay of brain aldehyde dehydrogenase activity using high-performance liquid chromatography with electrochemical detection. Anal Biochem 1986;158:6-11.
85. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D. Alpha-synuclein implicated Parkinson's disease catalyzes the formation of hydrogen peroxide in vitro. Free Radic Biol Med 2001;30:1163-70.
86. Volles MJ, Lee S-J, Rochet J-C, Shtilerman MD, Ding TT, Kessler JC et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001;40:7812-9.
87. Waldmeier PC, Delini-Stula A, Maitre L. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch Pharmac 1976;292:9-14.
88. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999;283:1482-8.
89. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science 1985;230:181-3.
90. Younkin SG, Goodridge B, Katz J, Lockett D, Nafziger MF, Usiak MF et al. Molecular forms of acetylcholine esterase in Alzheimer's disease. Fed Proc 1988;45:2982-8.
91. Zoratti HM, Szabo I. The mitochondrial permeability transition. Biochem Biophys Acta 1995;1241:139-76.